Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Neuphoria Therapeutics Inc. (NEUP)

Neuphoria agrees to all-share merger with UK-listed Scancell Holdings

Mixed Impact 5 of 5 m&a Written later

Neuphoria Therapeutics signed a merger agreement on July 23, 2026, under which Merger Sub will merge into Neuphoria and Neuphoria will become an indirect wholly owned subsidiary of Scancell Holdings plc. Neuphoria stockholders would receive Scancell ADSs at an exchange ratio of 37.77199 per share plus one contingent value right, and the deal is subject to shareholder approvals, financing and Nasdaq listing conditions. Neuphoria stockholders are expected to own about 11.1% of the combined company, and the filing describes the company as having no ongoing revenue and one employee.

Key points

  • Exchange ratio of 37.77199 Scancell ADSs per Neuphoria common share, plus one CVR per share
  • Pre-merger Neuphoria stockholders expected to own approximately 11.1% of the combined company
  • Closing conditions include Neuphoria stockholder approval and at least $75.0 million in gross PIPE proceeds; the merger must close by February 28, 2027 unless extended
  • Companion release says Neuphoria had $19.4 million in cash as of March 31, 2026 and a net loss of $0.5 million for the quarter ended March 31, 2026

The filing

CompanyNeuphoria Therapeutics Inc. (NEUP)
Form8-K, current report
Filed with the SECJul 23, 2026, 6:37 PM ET
Accession number0001213900-26-081052

Items reported: 1.01 Material Definitive Agreement5.01 Change in Control7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.